Azithromycin for uncomplicated severe acute malnutrition: study protocol for a pilot randomized controlled trial.

Amoxicillin Azithromycin Severe acute malnutrition Weight gain

Journal

Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536

Informations de publication

Date de publication:
20 Apr 2021
Historique:
received: 29 11 2020
accepted: 10 04 2021
entrez: 21 4 2021
pubmed: 22 4 2021
medline: 22 4 2021
Statut: epublish

Résumé

Given the high risk of infectious mortality among children with severe acute malnutrition (SAM), the World Health Organization recommends routine administration of a broad-spectrum antibiotic like amoxicillin as part of the management of uncomplicated SAM. However, evidence for the efficacy of amoxicillin to improve nutritional recovery or reduce mortality has been mixed. With a long half-life and evidence of efficacy to reduce mortality in high-risk populations, azithromycin is a potential alternative to amoxicillin in the management of SAM. In this pilot study, we aim to compare the efficacy of azithromycin to amoxicillin to improve nutritional outcomes in children with uncomplicated SAM. This pilot randomized controlled trial will enroll 300 children with uncomplicated SAM from 6 Centre de Santé et de Promotion Sociale in the Boromo health district in Burkina Faso. Eligible children are randomized to receive a single directly observed dose of oral azithromycin or a 7-day course of oral amoxicillin in addition to the standard package of care for uncomplicated SAM. Enrolled children are followed weekly until nutritional recovery, and all children return for a final study visit at 8 weeks after enrollment. Anthropometric indicators, vital status, and clinical outcomes are monitored at each visit and compared by arm. Primary feasibility outcomes include enrollment potential, refusals, loss to follow-up, and completeness of data collection. The primary clinical outcome is weight gain (g/kg/day) over the 8-week study period. This pilot trial will establish the feasibility of conducting a full-scale randomized controlled trial to evaluate alternative antibiotics in this setting and provide preliminary evidence for the efficacy of azithromycin compared to amoxicillin to improve outcomes for children with SAM. This trial was first registered on clinicaltrials.gov on 26 June 2018 ( NCT03568643 ).

Sections du résumé

BACKGROUND BACKGROUND
Given the high risk of infectious mortality among children with severe acute malnutrition (SAM), the World Health Organization recommends routine administration of a broad-spectrum antibiotic like amoxicillin as part of the management of uncomplicated SAM. However, evidence for the efficacy of amoxicillin to improve nutritional recovery or reduce mortality has been mixed. With a long half-life and evidence of efficacy to reduce mortality in high-risk populations, azithromycin is a potential alternative to amoxicillin in the management of SAM. In this pilot study, we aim to compare the efficacy of azithromycin to amoxicillin to improve nutritional outcomes in children with uncomplicated SAM.
METHODS METHODS
This pilot randomized controlled trial will enroll 300 children with uncomplicated SAM from 6 Centre de Santé et de Promotion Sociale in the Boromo health district in Burkina Faso. Eligible children are randomized to receive a single directly observed dose of oral azithromycin or a 7-day course of oral amoxicillin in addition to the standard package of care for uncomplicated SAM. Enrolled children are followed weekly until nutritional recovery, and all children return for a final study visit at 8 weeks after enrollment. Anthropometric indicators, vital status, and clinical outcomes are monitored at each visit and compared by arm. Primary feasibility outcomes include enrollment potential, refusals, loss to follow-up, and completeness of data collection. The primary clinical outcome is weight gain (g/kg/day) over the 8-week study period.
DISCUSSION CONCLUSIONS
This pilot trial will establish the feasibility of conducting a full-scale randomized controlled trial to evaluate alternative antibiotics in this setting and provide preliminary evidence for the efficacy of azithromycin compared to amoxicillin to improve outcomes for children with SAM.
TRIAL REGISTRATION BACKGROUND
This trial was first registered on clinicaltrials.gov on 26 June 2018 ( NCT03568643 ).

Identifiants

pubmed: 33879263
doi: 10.1186/s40814-021-00836-w
pii: 10.1186/s40814-021-00836-w
pmc: PMC8056624
doi:

Banques de données

ClinicalTrials.gov
['NCT03568643']

Types de publication

Journal Article

Langues

eng

Pagination

97

Subventions

Organisme : NICHD NIH HHS
ID : R21 HD100932
Pays : United States
Organisme : University of California San Francisco
ID : NA
Organisme : National Institute of Child Health and Human Development
ID : 1R21HD100932

Références

PLoS Med. 2020 Sep 15;17(9):e1003285
pubmed: 32931496
N Engl J Med. 2018 Apr 26;378(17):1583-1592
pubmed: 29694816
Am J Trop Med Hyg. 2020 Sep;103(3):1308-1310
pubmed: 32067626
Am J Trop Med Hyg. 2020 Sep;103(3):1291-1294
pubmed: 30734695
Lancet Glob Health. 2020 Feb;8(2):e288-e295
pubmed: 31981558
N Engl J Med. 2013 Jan 31;368(5):425-35
pubmed: 23363496
N Engl J Med. 2019 Jun 06;380(23):2207-2214
pubmed: 31167050
Lancet Glob Health. 2016 Jul;4(7):e464-73
pubmed: 27265353
N Engl J Med. 2016 Feb 4;374(5):444-53
pubmed: 26840134
PLoS Med. 2019 Jun 25;16(6):e1002835
pubmed: 31237871
Am J Epidemiol. 2003 May 15;157(10):940-3
pubmed: 12746247
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
PLoS One. 2013 Jul 17;8(7):e68699
pubmed: 23874731

Auteurs

Kieran S O'Brien (KS)

Francis I Proctor Foundation, University of California, San Francisco, 490 Illinois St, San Francisco, CA, USA.

Ali Sié (A)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Clarisse Dah (C)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Millogo Ourohire (M)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Ahmed M Arzika (AM)

Centre de Recherche et Interventions en Santé Publique, Niamey, Niger.

Valentin Boudo (V)

Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Elodie Lebas (E)

Francis I Proctor Foundation, University of California, San Francisco, 490 Illinois St, San Francisco, CA, USA.

William W Godwin (WW)

Francis I Proctor Foundation, University of California, San Francisco, 490 Illinois St, San Francisco, CA, USA.

Benjamin F Arnold (BF)

Francis I Proctor Foundation, University of California, San Francisco, 490 Illinois St, San Francisco, CA, USA.
Department of Ophthalmology, University of California, San Francisco, USA.

Catherine E Oldenburg (CE)

Francis I Proctor Foundation, University of California, San Francisco, 490 Illinois St, San Francisco, CA, USA. catherine.oldenburg@ucsf.edu.
Department of Ophthalmology, University of California, San Francisco, USA. catherine.oldenburg@ucsf.edu.
Department of Epidemiology & Biostatistics, University of California, San Francisco, USA. catherine.oldenburg@ucsf.edu.

Classifications MeSH